Mutations to kirromycin resistance occur in the interface of domains I and III of EF-Tu.GTP

FEBS Lett. 1994 Sep 26;352(2):118-22. doi: 10.1016/0014-5793(94)00937-6.

Abstract

The antibiotic kirromycin inhibits protein synthesis by binding to EF-Tu and preventing its release from the ribosome after GTP hydrolysis. We have isolated and sequenced a collection of kirromycin resistant tuf mutations and identified thirteen single amino acid substitutions at seven different sites in EF-Tu. These have been mapped onto the 3D structures of EF-Tu.GTP and EF-Tu.GDP. In the active GTP form of EF-Tu the mutations cluster on each side of the interface between domains I and III. We propose that this domain interface is the binding site for kirromycin.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Amino Acids / genetics
  • Anti-Bacterial Agents / pharmacology*
  • Base Sequence
  • Binding Sites
  • DNA Mutational Analysis
  • Drug Resistance, Microbial / genetics
  • Guanosine Diphosphate / metabolism
  • Guanosine Triphosphate / metabolism
  • Models, Molecular
  • Molecular Sequence Data
  • Mutation / genetics*
  • Peptide Elongation Factor Tu / chemistry
  • Peptide Elongation Factor Tu / genetics*
  • Peptide Elongation Factor Tu / metabolism
  • Protein Conformation
  • Pyridones / pharmacology
  • Salmonella typhimurium / drug effects

Substances

  • Amino Acids
  • Anti-Bacterial Agents
  • Pyridones
  • Guanosine Diphosphate
  • Guanosine Triphosphate
  • Peptide Elongation Factor Tu
  • mocimycin